MicroRNA‑218 enhances gastric cancer cell cisplatin sensitivity by targeting survivin

Zhang,Zhandong; Kong,Ye; Yang,Wei; Zhang,Bin; Ma,Fei; Liu,Hongxing; Hua,Yawei

doi:10.3892/etm.2018.6802

MicroRNA‑218 enhances gastric cancer cell cisplatin sensitivity by targeting survivin

Authors:
- Zhandong Zhang
- Ye Kong
- Wei Yang
- Bin Zhang
- Fei Ma
- Hongxing Liu
- Yawei Hua
View Affiliations

Affiliations: Department of General Surgery, Affiliated Tumor Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan 450008, P.R. China
Published online on: September 27, 2018 https://doi.org/10.3892/etm.2018.6802
Pages: 4796-4802

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer (GC) is one of the most prevalent types of cancer worldwide. Cisplatin based chemotherapy is the primary strategy implemented for the treatment of G; however, chemoresistance is a major problem. Previous studies have indicated that microRNAs (miRs) are associated with chemoresistance in various types of cancer and that miR‑218 specifically, serves important roles in the growth of GC cells. The present study assessed the potential biological roles of miR‑218 in GC cell cisplatin (DDP) resistance. The results obtained from a polymerase chain reaction assay indicated that the expression of miR‑218 was decreased in cisplatin resistant SGC7901/DDP cells compared with SGC7901 cells. Furthermore, MTT results indicated that the upregulation of miR‑218 expression significantly enhanced SGC7901/DDP cell sensitivity to DDP. The results of a dual‑luciferase assay indicated that survivin was a direct target gene of miR‑218. Results also demonstrated that miR‑218 was overexpressed in SGC7901/DDP cells and that the downregulation of survivin expression enhanced SGC7901/DDP cell sensitivity to DDP. Further study demonstrated that the upregulation of miR‑218 decreased the expression of survivin in SGC7901/DDP cells and induced apoptosis. The findings of the present study indicated that the induction of miR‑218 enhanced GC cell DDP resistance via the regulation of survivin, which may potentially benefit the clinical treatment of GC in the future.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Roder DM: The epidemiology of gastric cancer. Gastric Cancer. 5 Suppl 1:S5–S11. 2002. View Article : Google Scholar
3	Torre LA, Siegel RL, Ward EM and Jemal A: Global cancer incidence and mortality rates and Trends-an update. Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016. View Article : Google Scholar : PubMed/NCBI
4	Mesner PW Jr, Budihardjo II and Kaufmann SH: Chemotherapy-induced apoptosis. Adv Pharmacol. 41:461–499. 1997. View Article : Google Scholar : PubMed/NCBI
5	Kaufmann SH and Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 256:42–49. 2000. View Article : Google Scholar : PubMed/NCBI
6	Hannun YA: Apoptosis and the dilemma of cancer chemotherapy. Blood. 89:1845–1853. 1997.PubMed/NCBI
7	Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, et al: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 141:69–80. 2010. View Article : Google Scholar : PubMed/NCBI
8	Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
9	Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: A link between cancer genetics and chemotherapy. Cell. 108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
10	Kostova I: Platinum complexes as anticancer agents. Recent Pat Anticancer Drug Discov. 1:1–22. 2006. View Article : Google Scholar : PubMed/NCBI
11	Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
12	Ma L, Feldstein Teruya J and Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
13	Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, Teruya-Feldstein J, Bell GW and Weinberg RA: Therapeutic silencing of mir-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol. 28:341–347. 2010. View Article : Google Scholar : PubMed/NCBI
14	Cho WC: MicroRNAs: Potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 42:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
15	Hummel R, Hussey DJ and Haier J: MicroRNAs: Predictors and modifiers of chemo and radiotherapy in different tumour types. Eur J Cancer. 46:298–311. 2010. View Article : Google Scholar : PubMed/NCBI
16	Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
17	Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
18	Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP and Khan SA: Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene. 27:2575–2582. 2008. View Article : Google Scholar : PubMed/NCBI
19	Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, Iliopoulos D, Pilozzi E, Liu CG, Negrini M, et al: E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apopto-sis in gastric cancer. Cancer Cell. 13:272–286. 2008. View Article : Google Scholar : PubMed/NCBI
20	Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
21	Li Q, Yang Z, Chen M and Liu Y: Downregulation of microRNA-196a enhances the sensitivity of non-small cell lung cancer cells to cisplatin treatment. Int J Mol Med. 37:1067–1074. 2016. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Moriyama M, Tsukamoto Y, Fujiwara M, Kondo G, Nakada C, Baba T, Ishiguro N, Miyazaki A, Nakamura K, Hori N, et al: Identification of a novelhuman ankyrin-repeated protein homologous to CARP. Biochem Biophys Res Commun. 285:715–723. 2001. View Article : Google Scholar : PubMed/NCBI
24	Wang LL, Wang L, Wang XY, Shang D, Yin SJ, Sun LL and Ji HB: MicroRNA-218 inhibits the proliferation, migration, and invasion and promotes apoptosis of gastric cancer cells by targeting LASP1. Tumour Biol. 37:15241–15252. 2016. View Article : Google Scholar : PubMed/NCBI
25	Zhu W, Shan X, Wang TS, Shu YQ and Liu P: miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer. 127:2520–2529. 2010. View Article : Google Scholar : PubMed/NCBI
26	Hu Y, Xu K and Yagüe E: miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer. Breast Cancer Res Treat. 151:269–280. 2015. View Article : Google Scholar : PubMed/NCBI
27	Yang SM, Huang C, Li XF, Yu MZ, He Y and Li J: miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology. 306:162–168. 2013. View Article : Google Scholar : PubMed/NCBI
28	Farazi TA, Spitzer JI, Morozov P and Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011. View Article : Google Scholar : PubMed/NCBI
29	Zhu Y, Yu F, Jiao Y, Feng J, Tang W, Yao H, Gong C, Chen J, Su F, Zhang Y and Song E: Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res. 17:7105–7115. 2011. View Article : Google Scholar : PubMed/NCBI
30	Creevey L, Ryan J, Harvey H, Bray IM, Meehan M, Khan AR and Stallings RL: MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1. Mol Cancer. 12:232013. View Article : Google Scholar : PubMed/NCBI
31	Chen DQ, Pan BZ, Huang JY, Zhang K, Cui SY, De W, Wang R and Chen LB: HDAC 1/4-mediated silencing of microRNA-200b promotes chemoresistance in human lung adenocarcinoma cells. Oncotarget. 5:3333–3349. 2014. View Article : Google Scholar : PubMed/NCBI
32	He X, Dong Y, Wu CW, Zhao Z, Ng SS, Chan FK, Sung JJ and Yu J: MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating BMI1 poly-comb ring finger oncogene. Mol Med. 18:1491–1498. 2013.PubMed/NCBI
33	Li J, Ping Z and Ning H: MiR-218 impairs tumor growth andincreases chemo-sensitivity to cisplatin in cervical cancer. Int J Mol Sci. 13:16053–16064. 2012. View Article : Google Scholar : PubMed/NCBI
34	Uesugi A, Kozaki K, Tsuruta T, Furuta M, Morita K, Imoto I, Omura K and Inazawa J: The tumor suppressive microRNAmiR-218 targets the mTOR component Rictor and inhibits AKTphosphorylation in oral cancer. Cancer Res. 71:5765–5778. 2011. View Article : Google Scholar : PubMed/NCBI
35	Xin SY, Feng XS, Zhou LQ, Sun JJ, Gao XL and Yao GL: Reduced expression of circulating microRNA-218 in gastric cancer and correlation with tumor invasion and prognosis. World J Gastroenterol. 20:6906–6911. 2014. View Article : Google Scholar : PubMed/NCBI
36	Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998. View Article : Google Scholar : PubMed/NCBI
37	Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I and Reed JC: HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J. 22:2729–2740. 2003. View Article : Google Scholar : PubMed/NCBI
38	Singh N, Krishnakumar S, Kanwar RK, Cheung CH and Kanwar JR: Clinical aspects for survivin: A crucial molecule for targeting drug-resistant cancers. Drug Discov Today. 20:578–587. 2015. View Article : Google Scholar : PubMed/NCBI
39	Waligórska-Stachura J, Jankowska A, Waśko R, Liebert W, Biczysko M, Czarnywojtek A, Baszko-Błaszyk D, Shimek V and Ruchała M: Survivin-prognostic tumor biomarker in human neoplasms-review. Ginekol Pol. 83:537–540. 2012.PubMed/NCBI
40	Huang J, Lyu H, Wang J and Liu B: MicroRNA regulation and therapeutic targeting of survivin in cancer. Am J Cancer Res. 5:20–31. 2014.PubMed/NCBI